PRESENTATION TITLE
Molecular Risk Stratification in Early-Stage Lung Cancer

PRESENTER(S)
Johannes Ruediger Kratz, M.D.
Director, Advanced Minimally Invasive Thoracic Surgery, Assistant Professor of Surgery, UCSF, San Francisco, CA

PRESENTER BIO

Johannes R. Kratz, M.D is Assistant Professor of Surgery at UCSF. He is board-certified in Thoracic Surgery and specializes in treating disorders of the trachea, chest wall, lung, esophagus, and mediastinum. He is the Director of Minimally Invasive and Robotic Thoracic Surgery at UCSF.

Dr. Kratz's research interests include mechanisms of early-stage lung and esophageal cancer recurrence, biomarkers to personalize cancer treatment and immunotherapy approaches for thoracic tumors. His current research focuses on understanding the molecular and genetic profiles of high-risk tumors in early stages and developing targeted therapies to treat them. While a surgical research fellow at the UCSF Thoracic Oncology Laboratory, Dr. Kratz developed a test that more accurately predicts outcomes for patients with early-stage lung cancer. Now available to patients, this test has improved outcomes for those with high-risk lung cancer detected early.

Dr. Kratz earned his medical degree at Harvard Medical School, graduating magna cum laude. He completed a general surgery residency at Massachusetts General Hospital, followed by a fellowship in cardiothoracic surgery at UCSF. He also has a master's degree in philosophy from Stanford University.

Dr. Kratz is a member of the American College of Surgeons, Society of Thoracic Surgeons, Massachusetts Medical Society and American Society of Clinical Oncology. In 2017, he received the UCSF Health Exceptional Physician Award. He is the Van Auken Endowed Chair in Thoracic Oncology at UCSF.

VIEWING LOCATIONS

 Zoom Registration Link

LEARNING OBJECTIVES

• Identify the need for improved risk stratification in early-stage lung cancer.
• Define the rationale behind adjuvant therapy despite complete surgical resection for early-stage lung cancer.
• Assess how molecular risk classifiers are used to guide decisions about adjuvant therapy after surgery for stage IA-IIA lung cancer.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.